Plasma Therapy Market Size And Growth Industry Report By 2034

(MENAFN- Straits Research) Plasma Therapy Market Size

The plasma therapy market size was valued at USD 620 million in 2025 and is projected to grow from USD 669 million in 2026 to USD 1194 million by 2034 at a CAGR of 7.5% during the forecast period (2026-2034), as per Straits Research Analysis.

The plasma therapy market is experiencing significant transformation, driven by the expanding adoption of platelet-rich plasma (PRP) and regenerative therapies across orthopedics, dermatology, aesthetics, chronic wound care, and rehabilitation. Healthcare providers and clinics are increasingly integrating plasma-based treatments into standard protocols to enhance healing outcomes, supported by investments in specialized preparation systems, automation, and staff training. Technological advancements in plasma collection, separation, and purification are improving safety, consistency, and scalability, enabling more reliable and efficient therapy delivery. Rising sports-related injuries, musculoskeletal disorders, and neurological conditions further fuel demand, while manufacturers expand collection networks and production capacities to meet clinical needs. However, market growth faces challenges due to the limited availability of plasma donors and high costs of collection, processing, and therapy administration, which restrict supply and affect affordability in certain regions. The digitization of donor management, real-time plasma tracking, and the growth of regenerative medicine and aesthetic applications provide new opportunities, allowing players to optimize operations, enhance treatment accessibility, and broaden adoption across both traditional clinical and emerging outpatient and cosmetic settings.

Key Market Insights

North America dominated the market with the largest share of 43% in 2025. The Asia Pacific region is expected to be the fastest-growing region in the market during the forecast period at a CAGR of 14%. By type, the pure platelet-rich plasma segment accounted for the largest share of 45% in 2025. By source, the autologous segment is projected to grow at a CAGR of 7% over the forecast period. By source, the allogenic segment is projected to grow at a CAGR of 7.5% over the forecast period. By end user, the hospitals & clinics segment is projected to grow at a CAGR of 7.5% over the forecast period. By end user, the research institutes segment is projected to grow at a CAGR of 9% over the forecast period. By application, the orthopedic segment accounted for the largest share of 45% in 2025. The US plasma therapy market size was valued at USD 242 million in 2025 and is projected to reach USD 262 million in 2026.

Market Summary

Market Metric	Details & Data (2025-2034)
2025 Market Valuation	USD 620 Million
Estimated 2026 Value	USD 669 Million
Projected 2034 Value	USD 1194 Million
CAGR (2026-2034)	7.5%
Dominant Region	North America
Fastest Growing Region	Asia Pacific
Key Market Players	BioLife Plasma Services, Grifols International S.A., Biotest, CSL Ltd., Cambryn Biologics LLC

to learn more about this report Download Free Sample Report

Emerging Trends in Plasma Therapy Market Broader clinical application of platelet-rich plasma therapies

The use of platelet-rich plasma and regenerative therapies is moving from limited and experimental applications to broader clinical adoption across orthopedics, aesthetics, and chronic wound care. For instance, Japan's Act on theSafety of Regenerative Medicine provides a formal regulatory framework governing the use of plateletrich plasma and other regenerative therapies, with the Ministry of Health, Labour and Welfare actively overseeing and considering revisions to ensure safe clinical application as PRP moves toward broader medical use. Healthcare providers increasingly incorporate plasma-based treatments into standard therapeutic protocols to enhance healing outcomes. Clinics and manufacturers invest in specialized preparation systems and training to support consistent treatment delivery. As a result, the market evolves toward diversified applications with stronger clinical integration and patient acceptance.

Improvements in plasma collection to standardized and automated systems

Ongoing improvements in plasma collection and processing technologies drive a transition from manual and variable processes to more standardized and automated systems. Ongoing research on adaptive nomogram approaches adjusts the amount of plasma collected from each donor based on individual height and weight, enabling up to ~15 % more plasma to be safely collected per donation compared with traditional methods. Emerging microfluidic and lab on chip plasma separation devices are being developed that can rapidly separate plasma from whole blood with high efficiency (>99 % purity) in portable and automated formats suitable for point-of-care diagnostics. Companies adopt advanced separation and purification techniques to improve yield, safety, and product consistency. These advancements support scalability and reduce variability in therapeutic performance across patients. Thus, the market shifts toward more reliable and technology-driven plasma therapy solutions with enhanced operational efficiency.

Market Drivers Increasing prevalence of neurological disorders and growing sports-related injuries drives market

The increasing prevalence of immunological and neurological disorders increases demand for plasma-derived therapies. This demand impacts the market by driving higher consumption of immunoglobulins and other plasma-based products for long-term disease management. Healthcare providers rely more on these therapies due to their effectiveness in managing chronic and rare conditions. Manufacturers respond by expanding plasma collection networks and scaling production capacity to meet rising needs. As a result, the market grows with a strong demand-driven expansion of plasma-derived treatment supply.

The growing number of surgical procedures and sports-related injuries increases demand for regenerative plasma therapies such as platelet-rich plasma. A longterm epidemiological analysis projects that the number of sports related orthopedic injuries in elderly populations could reach approximately 111,245 cases by 2040, representing more than a 100% increase from 2021 levels if current trends continue This impacts the market by expanding the use of plasma therapies in orthopedics, rehabilitation, and post-surgical recovery. Healthcare providers adopt these treatments to accelerate healing and improve patient outcomes. Clinics and service providers increase availability of plasma therapy procedures to meet patient demand. As a result, the market expands with increased adoption in both clinical and outpatient care settings.

Market Restraints Limited availability of donors and high collection costs restrain plasma therapy market growth

The limited availability of plasma donors acts as a restraining factor in the plasma therapy market, which creates a mechanism where the supply of raw plasma remains constrained despite rising clinical demand. Manufacturers face difficulties in maintaining consistent production volumes of plasma-derived therapies. This restricts market growth as supply limitations directly impact treatment availability and adoption.

The high cost associated with plasma collection, processing, and therapy administration acts as another restraining factor in the market, where treatment affordability becomes a concern for healthcare systems and patients. Providers limit usage or prioritize essential indications due to budget constraints. This slows down adoption, especially in cost-sensitive regions and smaller healthcare facilities.

Market Opportunities Digitization of donor management and broadening of aesthetic applications offers growth opportunities for plasma therapy market players

The increasing use of digital technologies in donor management and plasma tracking offers growth opportunities for players by improving efficiency and transparency across the value chain. This creates opportunities to optimize donor recruitment, scheduling, and retention through data-driven approaches. Companies adopt digital platforms to monitor plasma quality, traceability, and inventory in real time. These capabilities enhance operational control and reduce losses during collection and processing. This supports market expansion by enabling more reliable supply management and scalable plasma therapy operations.

The growing focus on regenerative medicine and aesthetic applications offers growth opportunities for clinics and manufacturers to offer innovative, minimally invasive therapies for wound healing, orthopedics, and cosmetic procedures. Companies develop easy-to-use preparation kits and point-of-care systems to support rapid and consistent treatments. These solutions improve patient convenience and treatment accessibility, which supports market expansion by broadening the adoption of plasma therapies beyond traditional clinical applications.

Regional Insights North America: market dominance through establishment as a global r&d hub for plasma therapy and favorable reimbursement & insurance coverage

North America dominated the market with the largest share of 43% in 2025. North America has established itself as the primary Research & Development (R&D) hub for plasma therapy, combining cutting-edge scientific research, clinical innovation, and strong industry support. The region hosts a high concentration of leading biotechnology and medical device companies that focus on developing advanced plasma therapy products, such as automated PRP (Platelet-Rich Plasma) preparation systems, fibrin-based therapies, and novel plasma-derived formulations. These companies work closely with world-class hospitals and research institutions, including Mayo Clinic, Cleveland Clinic, Johns Hopkins, Stanford, Harvard, the University of Toronto, and McGill University which conduct extensive clinical trials and translational research across applications like orthopedics, wound care, dermatology, dental regeneration, nerve repair, and cardiac tissue therapy.

In Canada, the supportive healthcare system significantly contributes to the adoption of plasma therapies, particularly autologous PRP and related procedures. While most elective plasma therapy treatments such as those for aesthetics or minor orthopedic injuries are typically self-paid, certain medically necessary applications, especially in orthopedics, wound care, and chronic musculoskeletal conditions, can receive partial reimbursement or coverage through provincial health plans or hospital funding. This reimbursement framework reduces financial barriers for patients, encourages hospitals and clinics to offer plasma therapy, and promotes wider clinical adoption. Combined with Canada's highly structured healthcare infrastructure, well-equipped hospitals, and trained medical professionals, this creates a conducive environment for integrating plasma therapies into mainstream clinical practice.

In the US, there is a high adoption of PRP (Platelet-Rich Plasma) and other regenerative therapies across orthopedics, dermatology, and aesthetics due to several factors. Clinicians widely use PRP for musculoskeletal injuries such as tendon, ligament, and joint repair, as well as chronic wound management, because of its proven efficacy and safety profile. Plasma therapies are increasingly used in dermatology, hair restoration, and aesthetic medicine, with clinics introducing advanced PRP procedures (e.g., sonicated PRP) for tissue rejuvenation, broadening the clinical adoption base beyond traditional surgical or hospital settings. The number of adults over 65 is projected to reach 78 million by 2035, increasing the incidence of osteoarthritis, tendon degeneration, and slow-healing wounds, all of which are conditions where plasma therapies (PRP, autologous plasma) are applied.

Asia Pacific: fastest growth through growing prevalence of musculoskeletal & lifestyle-related conditions and early adopter of regenerative medicine and PRP therapies

The Asia Pacific region is expected to be the fastest-growing region in the market during the forecast period at a CAGR of 14%, driven by the growing prevalence of musculoskeletal and lifestyle-related conditions. Rapid urbanization, sedentary lifestyles, and an aging population have led to an increase in orthopedic disorders such as osteoarthritis, tendon injuries, ligament damage, and joint degeneration. Sports-related injuries are rising as participation in recreational and professional sports grows. Chronic conditions linked to modern lifestyles like obesity, diabetes, and sedentary work habits also contribute to joint pain, delayed wound healing, and tissue degeneration, all of which can be treated with PRP and regenerative plasma therapies. This surge in musculoskeletal and lifestyle-related health issues has created a high unmet medical need, driving hospitals, clinics, and specialty centers across APAC to adopt plasma-based regenerative treatments rapidly, making the region the fastest-growing market globally.

Japan has been an early adopter of regenerative medicine and PRP (Platelet-Rich Plasma) therapies due to its advanced healthcare system, strong government support, and proactive regulatory framework. The country implemented the Act on the Safety of Regenerative Medicine, which provides clear pathways for the clinical use and commercialization of autologous regenerative therapies, including PRP. Hospitals and specialized clinics in orthopedics, dermatology, and wound care quickly integrated PRP treatments, supported by extensive clinical research and university-led trials. High patient awareness, demand for advanced therapeutic options, and a strong culture of innovation in medical technology have allowed Japan to lead the adoption of regenerative therapies in the Asia Pacific region.

In India, hospitals and specialty clinics are increasingly offering plasma therapy services due to rising awareness of regenerative medicine and growing demand for minimally invasive treatments. Orthopedic centers, dermatology clinics, dental practices, and aesthetic centers are adopting PRP and plasma-derived therapies for applications such as joint and tendon injuries, wound healing, skin rejuvenation, and hair restoration. India's blood banking network collects approximately 10–11 million units of blood annually, which represents a substantial clinical resource that supports preparation of therapeutic plasma and plateletrich plasma for regenerative and transfusion uses.

By Type

The pure platelet-rich plasma segment accounted for the largest share of 45% in 2025, reflecting steady demand in hospitals, specialty clinics, and aesthetic centers worldwide. Growth in this segment is primarily fueled by the rising prevalence of musculoskeletal injuries, increasing demand for minimally invasive therapies, and high patient awareness of regenerative treatments.

The leukocyte-rich PRP segment is expected to grow at a CAGR of 9% during the forecast period due to its potential in conditions where controlled inflammation accelerates healing, such as chronic tendon and ligament injuries. Growth is driven by increasing clinical evidence supporting LPRP's efficacy, expansion of specialty clinics offering regenerative treatments, and rising investment in plasma therapy research, particularly in North America, Europe, and the Asia Pacific region.

By Source

The autologous segment is projected to grow at a CAGR of 7% during the forecast period. Autologous plasma is relatively easy to prepare and can be administered in outpatient clinics, hospitals, and specialized centers. Growth is supported by increased patient awareness, physician training in regenerative medicine, and investment in automated preparation systems that make autologous plasma therapy more efficient and reproducible.

The allogenic segment is projected to grow at a CAGR of 7.5% during the forecast period. Its growth is driven by applications where autologous plasma is unavailable or insufficient, such as pooled plasma therapies, specialized regenerative interventions, or certain research and clinical trials. Growth is supported by advances in donor screening, improved safety protocols, and increasing clinical evidence of allogenic plasma's efficacy, particularly in niche indications like chronic tendon repair, wound healing in immunocompromised patients, and experimental regenerative therapies.

By End User

The hospitals & clinics segment is projected to grow at a CAGR of 7.5% during the forecast period driven by high patient volumes, well-established healthcare infrastructure, and wide adoption of regenerative therapies in orthopedics, dermatology, wound care, dental, and aesthetic procedures. Hospitals and outpatient clinics offer PRP, PRF, and other plasma-based therapies as part of routine treatment, often supported by trained medical professionals and advanced preparation equipment.

The research institutes segment is projected to grow at a CAGR of 9% during the forecast period. Growth is driven by increasing investments in translational and clinical research, a rising number of clinical trials for new plasma therapy applications, and collaborations with hospitals and industry. Research institutions focus on exploring novel indications, validating efficacy, and optimizing preparation techniques for both autologous and allogenic plasma therapies.

By Application

The orthopedic segment accounted for the largest share of 45% in 2025. Hospitals, specialty orthopedic clinics, and sports medicine centers increasingly adopt plasma therapies due to their minimally invasive nature, faster recovery outcomes, and strong clinical evidence. Growth is driven by the rising prevalence of sports injuries, aging populations, and lifestyle-related musculoskeletal disorders, as well as increased awareness and adoption of regenerative medicine treatments.

The dermatology segment is projected to grow at a CAGR of 9% during the forecast period. Growth is driven by increasing demand for skin rejuvenation, scar treatment, hair restoration, and aesthetic procedures using PRP and plasma-derived therapies. Rising patient awareness, high spending on cosmetic and anti-aging treatments, and rapid adoption in dermatology clinics and medical spas contribute to accelerated growth.

Competitive Landscape

The plasma therapy market is moderately fragmented, comprising global biotechnology and medical device companies, hospitals and specialty clinics, and research institutions. Leading players compete primarily through comprehensive product portfolios (PRP, PRF, fibrin, and plasma proteins), advanced preparation and automation systems, strong clinical trial data, and established distribution networks, enabling them to serve orthopedic, dermatology, dental, wound care, and aesthetic applications worldwide. Emerging and regional players focus on cost-effective plasma therapy devices, localized manufacturing, niche applications, and flexible clinical support for smaller hospitals, clinics, or price-sensitive markets, particularly in the Asia Pacific and Latin America. The market is expected to grow further due to the rising prevalence of musculoskeletal and lifestyle-related disorders, increasing awareness of regenerative therapies, expansion of clinical research, supportive reimbursement policies, and technological advancements in plasma preparation, creating significant opportunities for both established and emerging providers.

List of Key and Emerging Players in Plasma Therapy Market BioLife Plasma Services Grifols International S.A. Biotest CSL Ltd. Cambryn Biologics LLC Bio Products Laboratory Ltd. China Biologic Products Inc. Kedrion Biopharma Octapharma LFB biopharmaceutical Kamada Ltd. Arthrex, Inc. RegenLab SA Zimmer Biomet Holdings, Inc. Eppendorf AG EmCyte Corporation Harvest Technologies Corporation Osiris Therapeutics, Inc. Biomet Biologics Recent Developments

In March 2026, CSL announced an expansion of plasma therapy and plasma-derived manufacturing facilities in Kankakee, Illinois, with an investment of USD 1.5 billion to boost production capacity. In February 2026, Grifols Egypt received regulatory certification from the European Medicines Agency for its integrated plasma-derived medicines hub, marking strategic recognition of its capacity to supply immunoglobulins, albumin, and coagulation factors. In September 2025, Kedrion Biopharma received FDA approval for QIVIGY® Immune Globulin 10% IV for the treatment of primary humoral immunodeficiency in adults, boosting access to plasma-derived therapies in the US. In August 2025, Kamada Ltd. received FDA approval for its plasma collection center in Houston, Texas, strengthening its capacity to collect both specialty and normal source plasma.

Report Scope

Report Metric	Details
Market Size in 2025	USD 620 Million
Market Size in 2026	USD 669 Million
Market Size in 2034	USD 1194 Million
CAGR	7.5% (2026-2034)
Base Year for Estimation	2025
Historical Data	2022-2024
Forecast Period	2026-2034
Report Coverage	Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends
Segments Covered	By Type, By Source, By Application, By End User
Geographies Covered	North America, Europe, APAC, Middle East and Africa, LATAM
Countries Covered	US, Canada, UK, Germany, France, Spain, Italy, Russia, Nordic, Benelux, China, Korea, Japan, India, Australia, Taiwan, South East Asia, UAE, Turkey, Saudi Arabia, South Africa, Egypt, Nigeria, Brazil, Mexico, Argentina, Chile, Colombia

to learn more about this report Download Free Sample Report

Plasma Therapy Market Segments By Type

Pure Platelet-rich Plasma Leukocyte-rich PRP Pure Platelet-rich Fibrin Leukocyte-rich Fibrin Plasma Proteins

By Source

Autologous Allogenic

By Application

Orthopedic Chronic Infectious Diseases Dermatology Dental Cardiac Muscle Injury Nerve Injury

By End User

Hospitals & Clinics Research Institutions

By Region

North America Europe APAC Middle East and Africa LATAM

MENAFN26032026004597010906ID1110909032